A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models

被引：0
|
作者：
Okpalanwaka, Izuchukwu F.
Daugherity, Elizabeth A.
McCormick, Amanda L.
Anderson, Trevor S.
Smith, Savanna L.
Lawrence, Caryn
Lowe, Devin B.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2024年 / 12卷 / 10期
关键词：
D O I：
10.1158/2326-6074.TUMIMM24-B010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B010
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 x αPD-L1 bispecific antibody-armed T cells
    Cho, Jaewon
    Tae, Nara
    Song, Yujeong
    Kim, Chae-Won
    Lee, Seung-Joo
    Ahn, Jae-Hee
    Lee, Kwang-Ho
    Lee, Byung-Hyun
    Kim, Byung Soo
    Chang, Sun-Young
    Kim, Dae Hee
    Ko, Hyun-Jeong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [2] Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells
    Yang, Rui
    Shen, Susu
    Gong, Cheng
    Wang, Xin
    Luo, Fang
    Luo, Fengyan
    Yang Lei
    Wang, Zili
    Xu, Shasha
    Ni, Qian
    Xue, Yan
    Fu, Zhen
    Zeng, Liang
    Fang, Lijuan
    Yan, Yongxiang
    Zhang, Jing
    Gan, Lu
    Yi, Jizu
    Zhou, Pengfei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Anti-tumor efficacy of SMARCA degraders in pre-clinical models of cancer
    Satyam, Leena Khare
    Sasmal, Sanjita
    Pothuganti, Manoj K.
    Sreevidya, M. R.
    Ettam, Ashokk
    Nunna, Sireesha
    Roshaiah, Marla
    Chithaluru, Shankaraiah
    Pallepati, Rangarao
    Pawar, Amitkumar A.
    Narukulla, Leela P.
    Sripathi, Raghunadh A.
    Tgore, Suraj
    Nankar, Rakesh P.
    Charamanna, K. B.
    Gowda, Nagesh S.
    Aithal, Kiran
    Samiulla, D. S.
    Mukherjee, Subhendu
    Chelur, Shekar
    Nellore, Kavitha
    Daginakatte, Girish
    Ramachandra, Murali
    Samajdar, Susanta
    CANCER RESEARCH, 2019, 79 (13)
  • [4] CD3/PD-L1 bispecific aptamer enhances immune cytotoxicity against PD-L1 positive anaplastic thyroid cancer cells
    Ning, Qingyang
    Zhang, Xinyue
    Liu, Jiaye
    Li, Zhihui
    ASIAN JOURNAL OF SURGERY, 2024, 47 (09) : 4144 - 4146
  • [5] IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumors
    Kim, Jeong-kook
    Jeon, A-Ra
    Park, Jihyun
    Choi, Ji Yea
    Park, Ji Eun
    Song, Sun Kwang
    Choi, Ji Hye
    Shin, Heewook
    Lee, Ji Hye
    Yun, Ji Hye
    Ahn, Yoen Hee
    Kim, Heung Tae
    CANCER RESEARCH, 2022, 82 (12)
  • [6] PD-L1 blockade enhances anti-tumor efficacy of NK cells
    Oyer, Jeremiah L.
    Gitto, Sarah B.
    Altomare, Deborah A.
    Copik, Alicja J.
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [7] A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
    Cui, Xiaopei
    Jia, Huifeng
    Xin, Hong
    Zhang, Lei
    Chen, Shi
    Xia, Simin
    Li, Xue
    Xu, Wei
    Chen, Xiaofang
    Feng, Yujie
    Wei, Xiaoyue
    Yu, Haijia
    Wang, Yanting
    Zhan, Yifan
    Zhu, Xiangyang
    Zhang, Xuemei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [8] Anti-tumor effectiveness of a novel bispecific antibody that blocks both PD-L1 and LAG-3
    Zhang, Chenxing
    Liu, Jiaxin
    Sun, Minglv
    Gu, Tiejun
    Meng, Xiangyu
    Zhu, Shidong
    Zhang, Youfeng
    Wang, Linlin
    Chen, Yan
    Zhang, Daguang
    Wu, Yongge
    MOLECULAR IMMUNOLOGY, 2025, 182 : 30 - 40
  • [9] Pre-clinical characterization of avelumab (anti-human PD-L1) reveals an enhanced anti-tumor efficacy in hIgG1 isotype
    Qui, Y.
    Prior, W. W.
    Abdiche, Y.
    Chen, W.
    Potluri, S.
    Chaparro-Riggers, J.
    Patel, P.
    Lin, J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S93 - S93
  • [10] Dual blockade of PD-L1 and LAG-3 using a bispecific antibody improves anti-tumor immunity
    Ni, Haiqing
    Qiu, Yajing
    Jing, Hua
    Zhang, Pan
    Chen, Bingliang
    Wu, Zhihai
    Zhou, Shuaixiang
    Yu, Michael
    Liu, Junjian
    CANCER RESEARCH, 2020, 80 (16)
12345